Replies to post #46102 on NanoViricides Inc. (NNVC)

[BonelessCat]

See, you are another of those who see everything in isolation. Dengue is only one of the drugs currently in late pre-clinical trials. FluCide is another. Then there is HIV, HSV, and Viral Conjunctivitis. You need to include those in both analysis and valuation. Although separate tests, each will be used as proof of the platform. Once one enters trials, the others will quickly follow.

Also, you keep ignoring offshore use in high need, hard hit regions. NNVC does not need FDA approval for use in foreign domains. Yes, a tox study would be needed, but a ministry of health can approve DengueCide for use.

[BonelessCat]

>>Without evidence of...cGMP manufacturing progress..."

Interesting phrasing. Without evidence of cGMP facility. You are usually very precise with your word choices. You are not saying there isn't one. You are saying there is no evidence of one. Hmm. Do you know something we don't? Are you saying something is already there, but the company hasn't publicly announced anything? A cGMP facility would certainly threaten your short position. No wonder you are posting so much this weekend. Just a permit for one would would be evidence and blow you out of the water.